Trump administration announces funding for PTSD research on ibogaineWIRED investigation examines Jensen Huang's comments on defining women's power in techWalmart launches early Black Friday promotions on select giftsMint Mobile offers $500 discount on select new phones for new customers signing up for a yearRussia and Iran criticize U.S. Caspian task force amid reports of joint sanction evasion effortsNewly elected US lawmakers pose for traditional group photo at Capitol ahead of 120th Congress openingUS existing home sales drop to lowest monthly level in yearsPro-Palestine philanthropist faces US extradition hearing in SpainLewisham Islamic Centre criticizes charity watchdog over warning on Palestine commentsSenegalese wrestlers succeed in beach wrestling at Dakar Youth OlympicsUS nonprofits file lawsuit seeking pause on advanced AI model trainingDemocrats convene in Denver to discuss party direction after midterm victoriesUS releases report on $12bn from Venezuelan oil, mineral resourcesPope Leo XIV urges Catholic Church to address clergy sexual abuseShooting near White House results in death, suspect later found dead
All fact checks
AI analysis

Fact check

“In September 2019 the FDA proposed a rule setting requirements for pre‑market applications and review procedures.”
UnverifiableConfidence: LOW

Reasoning

The excerpt from the Reason.com article directly confirms the claim, mentioning the date (September 2019) and the nature of the rule (requirements for pre‑market applications and review procedures). No contradictory evidence is presented.

On confidence: The provided source explicitly states that in September 2019 the FDA proposed a rule that set forth requirements related to the content and format of pre‑market applications and the procedure for FDA review.

Important context

The rule was part of broader FDA efforts to address a backlog of nicotine product applications and was referenced in a lawsuit concerning application deadlines.

Evidence

Supporting (1)

Limitations

The assessment relies on a single secondary source; primary FDA documents were not consulted. However, the source provides a clear statement supporting the claim. No independent origin corroborated this claim, so it cannot be verified and confidence cannot be high.

Last verified:
Oct 1, 2026, 4:41 AM CDT
Pipeline:
2.1.0
Claim type:
Factual

Where this claim appeared

The FDA Promises To Streamline the Dauntingly Complex Rules for Approving Nicotine Products

Reason · Jacob Sullum